A multiancestry polygenic risk score for hypertrophic cardiomyopathy is developed and its association with the disease in a heterogeneous national population is demonstrated and support the integration of multiancestry PRSs into HCM risk assessment and prognostication.
Abstract
Hypertrophic cardiomyopathy (HCM) has traditionally been considered a Mendelian disease driven by pathogenic or likely pathogenic variants in sarcomere-encoding genes (SARC-HCM-P/LP). However, these variants explain only one-third of cases, and variable penetrance suggests additional polygenic contributions. Existing HCM polygenic risk scores (PRSs), largely derived from European-ancestry cohorts, have limited generalizability. Here we develop a multiancestry PRS using summary statistics from the BioBank Japan, Million Veteran Program and a meta-analysis of seven European-ancestry cohorts and evaluate its association with HCM in a USA-based multiancestry population. Individuals with the highest PRS quintile had a 2.11-fold increased risk of HCM in the overall population and nearly 70-fold higher risk among SARC-HCM-P/LP carriers. The PRS improved risk stratification and showed trends toward improved ancestry-specific prediction. Among individuals with HCM, a higher PRS was also associated with adverse cardiovascular outcomes. These findings support the integration of multiancestry PRSs into HCM risk assessment and prognostication. Bal et al. develop a multiancestry polygenic risk score for hypertrophic cardiomyopathy and demonstrate its association with the disease in a heterogeneous national population.
It is shown that the published hypercholesterolemia PRS (PGS000936) can effectively stratify risk and identify individuals with a high genetic burden in a real-world German clinical setting, supporting its clinical utility when appropriately calibrated for the local population.
L. Bundalian, A. Velluva, E. Gjermeni et al.· medRxiv· 0 citations
These findings replicate a significant diagnostic yield of molecular genetic testing in individuals with dilated cardiomyopathy but extend the relevance of genetic testing beyond traditionally selected HF subgroups, and underscore the importance of including non-European and admixed populations in cardiovascular genomi...
I. Lima, Lucas Vieira Lacerda Pires, M. A. C. E. Silva et al.· JACC: Advances· 0 citations
Findings reinforce the concept of HCM as a spectrum of diseases rather than a single genetic entity, setting the stage for more individualised approaches to diagnosis, counselling and management.
Clara Saldarriaga· Cardiac failure review· 0 citations
Most patients with MYH7-related HCM presented with a benign phenotype over the long term, and the risks of AF, SCD, and worsening HF throughout life justify regular monitoring, and the need to look for particular genetic profiles that may potentially help tailored management strategies.
Catarina Gregório, M. Vilela, Ana Beatriz Garcia et al.· Revista Portuguesa de Cardio...· 0 citations
Investigating the utility of genome-wide association study - derived PRS and pathway-specific PRS in the Latvian population and demonstrating superior discrimination compared to pathway-specific PRS found incorporation of PRS enhances early-onset CAD risk prediction.
E. Kanašniece, Elita Ozola, L. Bardina et al.· American Heart Journal Plus:...· 0 citations
Introduction Ischemic stroke (IS) is a leading cause of morbidity and mortality, and predicting events remains challenging. Polygenic risk scores (PRSs) aggregate genetic variants, but performance varies across ancestries and remains modest, particularly in non-European populations. Methods We compared Bayesian PRS met...
N. Armstrong, V. Srinivasasainagendra, Amit Patki et al.· Frontiers in Bioinformatics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.